BioLineRx, Ltd. (BLRX)

Check out top investors' recommendation for BLRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company’s development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sector:
N/A
Industry:
N/A
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 03, '18     4.00  Oct 03, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jul 30, '18     4.00  Jul 30, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   May 22, '18     4.00  May 22, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 06, '18     4.00  Mar 06, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 17, '18     4.00  Jan 17, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 21, '17     4.00  Nov 21, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 26, '17     4.00  Sep 26, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 09, '17     4.00  Aug 09, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   May 26, '17     4.00  May 26, '18  N/A 
Jason Kolbert Maxim Group Buy   May 18, '17     3.00  May 18, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 12, '16   1.09  7.00  Jan 12, '17  -17.43% 
Jason Kolbert Maxim Group Buy   Nov 16, '15   1.29    Nov 16, '16  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 05, '15   1.45  7.00  Nov 05, '16  -28.97% 
Joseph Pantginis Roth Capital Partners LLC Buy   Jun 22, '15   2.15    Jun 22, '16  -63.26% 
Ram Selvaraju Aegis Capital Buy   May 21, '14   1.96    May 21, '15  -4.08% 
Charles Graham Unaffiliated Buy   Oct 05, '13   2.66  5.00  Oct 05, '14  -42.86% 
Mesut Dogan Unaffiliated Buy   Sep 20, '13   2.25  5.00  Mar 20, '14  11.11% 
Ram Selvaraju Aegis Capital Buy   Sep 09, '13   2.30    Sep 09, '14  -27.39% 
Enoch Kuo Unaffiliated Sell   Apr 01, '13   1.64  1.00  Apr 01, '14  -35.98%